Families of those with sickle cell disease in Philadelphia area hope and advocate for a cure
Thursday marked World Sickle Cell Awareness Day, which focuses on supporting families and encouraging more research on the most common genetic disorder in the United States.
"He looks normal one minute and then the next, something is wrong," Kaliph's mom, Antoinelle Whitmore, said. "You're always on the edge. You never know."
Whitmore said her son has a mild case of the genetic disorder, which causes blood cells to become sickle-shaped. The cells then pile up and prevent oxygen delivery around the body, causing debilitating pain.
Zemoria Brandon lost her husband to sickle cell disease. Now she works with Philadelphia's Sickle Cell Disease Association, which is raising awareness by lighting buildings in red this week.
CBS News Philadelphia
"It does affect people of African, Caribbean, Latino ancestry in the greatest numbers. But there are other groups … that are also affected in smaller percentages. So we just want to make sure that people know …it has a global impact," Brandon said.
"The research is ongoing, and we're looking and hoping for a universal cure," Brandon said.
Kaliph's mom said he's lucky so far to have only needed one blood transfusion. She lives in fear, but she's hopeful more awareness and research will lead to better treatments that are more accessible
"I want him to reach for the stars. I want him to be his true authentic self," she said. "I want him to be the vibrant person he is now and not let anything hold him back."
For people with severe cases of sickle cell disease, there are bone marrow transplants, and CHOP has developed a gene therapy.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
23 minutes ago
- Yahoo
Astrana Health completes acquisition of Prospect Health for $708m
US-based Astrana Health has closed its acquisition of Prospect Health, a care delivery network, for a total purchase price of $708m. With a network of more than 11,000 providers, Prospet Health offers coordinated care to approximately 600,000 members. The network covers various states in the US, including Arizona, Rhode Island, Southern California, and Texas, serving Medicaid, Medicare Advantage, and Commercial business lines. Prospect Health's operations include a health plan, a management services organisation, a speciality pharmacy, and an acute care hospital. The acquisition price reflects a decrease from the initially stated $745m in November 2024. Astrana president and CEO Brandon Sim said: "We are excited to welcome Prospect Health's physicians, providers, and team members to Astrana Health. "Together, we will further accelerate our mission to drive consistent, coordinated, high-quality patient outcomes at scale, ultimately driving greater value across the healthcare ecosystem." Astrana projects that Prospect Health will contribute a total revenue of approximately $1.2bn and $81m in adjusted EBITDA annually. In addition, Astrana anticipates achieving $12m to $15m of synergies within the next one to one-and-a-half years. The company has updated its 2025 full-year guidance to a revenue range of $3.1bn to $3.3bn and adjusted EBITDA between $215m and $225m, considering Prospect Health's half-year contribution. Following the transaction, Astrana's net debt is expected to be approximately $700m. The company's management is focused on lessening the net leverage ratio to below 2.5 times within the next one to one-and-a-half years. Truist Securities led a consortium of banks that offered the term loan for the purchase. J P Morgan acted as the exclusive financial adviser to Astrana during the transaction. The acquisition follows Astrana's previous acquisition of Collaborative Health Systems in October last year, which also aimed to broaden its care delivery capabilities. "Astrana Health completes acquisition of Prospect Health for $708m" was originally created and published by Hospital Management, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
24 minutes ago
- Yahoo
Summit Therapeutics stock rises after report of potential $15B AstraZeneca deal
-- Summit Therapeutics (NASDAQ:SMMT) stock rose 5% on Thursday while AstraZeneca (NASDAQ:AZN) shares fell 2% following a Bloomberg report that the companies are in discussions for a potential $15 billion partnership deal. According to the report, AstraZeneca is considering a licensing agreement for Summit's ivonescimab lung cancer treatment. The deal structure could include a multi-billion dollar upfront payment followed by milestone payments that could bring the total value to approximately $15 billion over time. Summit has also reportedly been in talks with other major pharmaceutical companies about the experimental cancer drug, suggesting competitive interest in the treatment. The negotiations are still ongoing, and terms are being finalized, though the discussions could still fall apart or Summit might choose a different partner. Related articles Summit Therapeutics stock rises after report of potential $15B AstraZeneca deal What could a shift in Intel's foundry strategy bring? Growth funds favor Makemytrip and SK Hynix: BofA Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
24 minutes ago
- Yahoo
Lizzo Fires Back at Ozempic Critics: ‘This S**t Is Hard'
Lizzo is once again hitting back at busybodies and skeptics who won't stop speculating on her weight loss. In an interview with Women's Health, the 37-year-old singer aimed to make her mindset, motivation, and methods crystal clear. She directed some comments at those who, despite her previous statements, insist that Lizzo's changing figure is attributed to GLP-1 drugs. Lizzo shared with writer Jessica Herndon that she's recently received questions from fans, like, 'Are you taking Ozempic?' and 'What happened when you said it's okay to be fat?' This is not to say that the artist seeks to shade those who turn to GLP-1 drugs in their healthcare journeys. She said, 'If I did all of this on Ozempic....I would be just as proud of myself, because this s**t is hard.' For the 'About Damn Time' singer, this wasn't a weight loss journey, but a weight release journey. Because, as Lizzo sees it, she didn't actually lose anything. 'It's okay to release weight...[and] it's okay to gain weight after you've released weight,' she says. In January, Lizzo posted photos to her Instagram wearing workout gear paired with an ecstatic caption. 'I reached my weight release goal,' she wrote, adding a motivational message for fans about achieving their own goals. 'I wanted to be 'big-girl skinny,'' she tells Women's Health. 'Every big girl knows what I'm talking about. Big-girl skinny is 250 pounds.' This meant a balance of feeling like herself while reducing back pain and health concerns she struggled with. The change, she explains, came from consistent exercise and a nutritious diet with lean proteins and vegetables. Each week, she performs a mix of strength training and cardio for three days, and dedicates two days to 45-minute cardio workouts. It wasn't about chasing thinness—only feeling better in her body, on her terms.
